Optimizing Zanubrutinib Dosing in Patients: A PBPK‐BO Model Approach to Drug–Drug Interactions and Patients with Hepatic Impairment

Documenti analoghi

• Physiologically Based Pharmacokinetic Modeling of Lurasidone, an Antipsychotic Drug: Impact of CYP3A4 Polymorphisms and Hepatic Impairment on Exposure and Dose Optimization
  di: Seung‐Hyun Jeong, et al.
  Pubblicazione: (2026)
• Determination of Vatiquinone Drug‐Drug Interactions, as CYP450 Perpetrator and Victim, Using Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation
  di: Lucy Lee, et al.
  Pubblicazione: (2024)
• Physiologically Based Pharmacokinetic (PBPK) Model to Predict the Magnitude of Drug–Drug Interaction Between Fezolinetant and CYP1A2 Inhibitors
  di: Mary P. Choules, et al.
  Pubblicazione: (2025)
• A Model‐Informed Drug Development Approach Supporting the Approval of an Unstudied Valbenazine Dose for Patients With Tardive Dyskinesia
  di: Hoa Q. Nguyen, et al.
  Pubblicazione: (2024)
• Physiologically Based Pharmacokinetic Modeling of Lemborexant: Exploration of Doses for Populations with Hepatic Impairment
  di: Wanhong Wu, et al.
  Pubblicazione: (2025)